2025 Biopharma Investment Trends and Therapeutic Advances in Pharma and Biotech

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.In 2025, VC funds are expected to follow the data when investing in biopharma companies, as high profile failures and long timeframes for revenue have shifted investment away from phase I. To attract VC dollars, companies must bring solid data to the table, according to Pitchbook's 2025 outlook. Additionally, GLP-1 receptor agonists, known for their use in diabetes and obesity treatments, have now expanded into the cardiovascular and sleep apnea markets. They also show potential in other indications such as cancer, addiction, and neurodegenerative diseases. Applied Therapeutics has faced challenges with a significant drop in share price due to FDA rejection and a warning letter. On a positive note, Lilly's Zepbound has received approval as the first-ever sleep apnea drug for adults with obesity. Other companies such as Vertex have also received FDA approval for new treatment options. Novo's recent blunder highlights the high investor expectations for weight loss drugs. Overall, the biopharma industry is constantly evolving with new approvals and advancements in various therapeutic areas.